Search | Clinical Trials Finder

Conditions: HER2-positive Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer
Interventions: lapatinib ditosylate, paclitaxel, trastuzumab, therapeutic conventional surgery, pharmacological study, laboratory biomarker analysis; Drug · Biological · Procedure + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 20 Years and older · Female only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Metastatic Breast Cancer
Interventions: 18F Fluoroestradiol Radiopharmaceutical with PET/CT; Drug
Lead sponsor: GE Healthcare; Industry
Eligibility: 18 Years to 99 Years · Female only
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 24
States / cities: Flagstaff, Arizona • Cerritos, California • Duarte, California + 20 more

Conditions: Breast Cancer, Metastatic Breast Cancer
Interventions: trastuzumab, vinorelbine; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2018
U.S. locations: 3
States / cities: Boston, Massachusetts

Conditions: Breast Cancer
Interventions: Ribociclib, letrozole; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 6
States / cities: Sedona, Arizona • Long Beach, California • Charlotte, North Carolina + 3 more

Conditions: Ovarian Neoplasms, Peritoneal Neoplasms, Fallopian Tube Neoplasms, Triple Negative Breast Neoplasms, HER2 Negative Breast Neoplasms, Hormone Receptor Positive Breast Neoplasms, Endometrial Neoplasms, Carcinoma, Non-Small-Cell Lung, Cholangiocarcinoma, Gallbladder Carcinoma, Adenoid Cystic Carcinoma
Interventions: Felmetatug Vedotin, Pembrolizumab; Drug
Lead sponsor: Seagen, a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 22
States / cities: Aurora, Colorado • Denver, Colorado • Celebration, Florida + 9 more

Conditions: Estrogen Receptor and/or Progesterone Receptor Positive, HER2/Neu Negative, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions: Fulvestrant, Laboratory Biomarker Analysis, Palbociclib, Questionnaire Administration, Aromatase Inhibitors; Drug · Other
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 65 Years and older · Female only
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 3
States / cities: Edgewood, Kentucky • Cleveland, Ohio • Columbus, Ohio

Conditions: Breast Cancer
Interventions: nivolumab, paclitaxel (PTX), nivolumab placebo, anthracycline, cyclophosphamide, Endocrine Therapy, Surgery; Biological · Drug · Other + 1 more
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 521 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 30
States / cities: Mobile, Alabama • Greenbrae, California • Whittier, California + 27 more

Conditions: HER-2 Positive Malignant Carcinoma of Breast, HER-2 Protein Overexpression, HER2-positive Metastatic Breast Cancer
Interventions: 89Zr-ss-pertuzumab PET/CT; Combination Product
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: HER2-positive Breast Cancer, HER2+ Breast Cancer
Interventions: Carvedilol, Empagliflozin; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Breast Cancer, Hormonreceptor Positive, Her2-normal, Postneoadjuvant Treatment With CDK 4/6 Inhibitor, CPS-EG Score
Interventions: Palbociclib PD-0332991, Placebo; Drug
Lead sponsor: GBG Forschungs GmbH; Other
Eligibility: 18 Years and older · Female only
Enrollment: 1,250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Breast Cancer
Interventions: Letrozole, Palbociclib, Goserelin, Oncotype DX Breast Recurrence Score; Drug · Diagnostic Test
Lead sponsor: NSABP Foundation Inc; Network
Eligibility: 18 Years and older · Female only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 11
States / cities: Fountain Valley, California • Laguna Hills, California • Long Beach, California + 5 more

Conditions: Breast Cancer
Interventions: trastuzumab, trastuzumab emtansine; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 1,486 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2024
U.S. locations: 60
States / cities: Anchorage, Alaska • Long Beach, California • Orange, California + 49 more

Conditions: HER2-Positive Primary Breast Cancer, Residual Invasive Breast Cancer
Interventions: DS-8201a, T-DM1; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 1,600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 126
States / cities: Anaheim, California • Baldwin Park, California • Bellflower, California + 94 more

Conditions: Breast Cancer
Interventions: Fulvestrant, Alpelisib, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 572 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 34
States / cities: Chandler, Arizona • Scottsdale, Arizona • Fayetteville, Arkansas + 31 more

Conditions: Breast Cancer
Interventions: Trastuzumab Emtansine, Trastuzumab, Pertuzumab, Paclitaxel, Epirubicin, Doxorubicin, Docetaxel, Cyclophosphamide, 5-Fluorouracil; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 1,846 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 50
States / cities: Scottsdale, Arizona • Oakland, California • Roseville, California + 44 more

Conditions: Breast Cancer
Interventions: Positron emission tomography (PET), Trastuzumab, Pertuzumab; Procedure · Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2027
U.S. locations: 10
States / cities: Birmingham, Alabama • Washington D.C., District of Columbia • Indianapolis, Indiana + 6 more

Conditions: Male Breast Carcinoma, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7
Interventions: Laboratory Biomarker Analysis, Lapatinib Ditosylate, Paclitaxel, Trastuzumab; Other · Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 305 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2024
U.S. locations: 317
States / cities: Tucson, Arizona • Fort Smith, Arkansas • Burbank, California + 222 more

Conditions: Neoplasms, Breast
Interventions: Lapatinib, Trastuzumab; Drug · Biological
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 8,381 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2021
U.S. locations: 260
States / cities: Mobile, Alabama • Anchorage, Alaska • Tucson, Arizona + 221 more

Conditions: Breast Cancer
Interventions: Amcenestrant (SAR439859), Letrozole; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 6
States / cities: Tucson, Arizona • Los Angeles, California • Fort Wayne, Indiana + 3 more

Conditions: Adult Solid Neoplasm, Extensive Stage Lung Small Cell Carcinoma, HER2/Neu Negative, HER2/Neu Positive, Male Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain, Recurrent Breast Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Recurrent Lung Small Cell Carcinoma, Recurrent Melanoma, Stage IV Breast Cancer AJCC v6 and v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Stage IV Lung Non-Small Cell Cancer AJCC v7
Interventions: Cognitive Assessment, Gamma-Secretase Inhibitor RO4929097, Laboratory Biomarker Analysis, Stereotactic Radiosurgery, Whole-Brain Radiotherapy; Procedure · Drug · Other + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 2
States / cities: Boston, Massachusetts • Houston, Texas

Conditions: Early Breast Cancer
Interventions: LEE011 (ribociclib), letrozole; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 4
States / cities: Fayetteville, Arkansas • Los Angeles, California • Boston, Massachusetts + 1 more

Conditions: High Grade Epithelial Ovarian Cancer, High Grade Serous Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Endometrial Cancer, Non-small Cell Lung Cancer, Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (NSCLC), Mesothelioma, Breast Adenocarcinoma, Triple Negative Breast Cancer, Hormone Receptor-positive/Her2 Negative Breast Cancer, Platinum-resistant Ovarian Cancer (PROC), Platinum Sensitive Ovarian Cancer (PSOC), Primary Refractory Ovarian Cancer, Uterine Cancer
Interventions: Rina-S, Carboplatin, Bevacizumab, Pembrolizumab; Drug
Lead sponsor: Genmab; Industry
Eligibility: 18 Years and older
Enrollment: 884 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 37
States / cities: Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 32 more

Conditions: Breast Cancer
Interventions: 5-Fluorouracil, Carboplatin, Cyclophosphamide, Docetaxel, Doxorubicin, Epirubicin, Paclitaxel, Pertuzumab, Placebo, Trastuzumab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 4,804 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2024
U.S. locations: 114
States / cities: Scottsdale, Arizona • Everett, California • Greenbrae, California + 92 more

Conditions: HER2-positive Breast Cancer, HER2 Gene Mutation, HER-2 Gene Amplification, HER2 Positive Gastric Cancer, Salivary Gland Cancer, Salivary Gland Tumor, Salivary Gland Carcinoma, Salivary Gland Neoplasms, Lung Cancer, Colo-rectal Cancer, Rare Diseases, Solid Tumor, Recurrent Gastric Cancer, Recurrent Colon Cancer, Recurrent Breast Cancer, Head and Neck Cancer, Head and Neck Carcinoma, Bladder Cancer, Cervical Cancer, Liver Cancer, Bile Duct Cancer, Urologic Cancer, Pancreatic Cancer, Prostate Cancer, Recurrent Prostate Cancer, Rectal Cancer, Recurrent Ovarian Carcinoma, Recurrent Renal Cell Cancer, Rectal Cancer Stage II, Rectal Cancer Stage I, Rectal Cancer Stage III, Skin Cancer, Mouth Cancer, Lip Cancer Stage I, Tongue Cancer, Breast Neoplasm Malignant Primary, Larynx Cancer, Tonsil Cancer, Palate Cancer, Mucoepidermoid Carcinoma, Primary Peritoneal Carcinoma, Mucinous Adenocarcinoma Gastric, Mucinous Breast Cancer Recurrent, Cholangiocarcinoma
Interventions: A166; Drug
Lead sponsor: Klus Pharma Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 10
States / cities: Sarasota, Florida • Boston, Massachusetts • Detroit, Michigan + 7 more

Search by objective public record fields.

Lapatinib Ditosylate, Trastuzumab, Paclitaxel, and Surgery in Treating Patients With Breast Cancer

Clinical Utility of FES F18 PET/CT in Metastatic Breast Cancer Patients

Trastuzumab and Vinorelbine in Advanced Breast Cancer

A Companion Sample Collection Protocol to Support the Discovery of Breast Cancer Aberrations With Treatment of CDK4/6 Therapy/LEE011/Ribociclib

A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors

Endocrine Therapy Fulvestrant & Palbociclib or Aromatase Inhibitor Therapy in Treating Older Patients With Hormone Responsive Breast Cancer That Cannot Be Removed by Surgery

Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer

Testing a New Imaging Agent to Identify Cancer

HER2HEART-US: Prevention of Cardiotoxicity in Breast Cancer Patients Receiving HER2-directed Therapy

A Study of Palbociclib in Addition to Standard Endocrine Treatment in Hormone Receptor Positive Her2 Normal Patients With Residual Disease After Neoadjuvant Chemotherapy and Surgery

Biological and Clinical Effects of Palbociclib With Ovarian Suppression and Letrozole in the Neoadjuvant Treatment of Breast Cancer

A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE)

A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)

Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment.

A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer

Pertuzumab and Trastuzumab as Neoadjuvant Treatment in Patients With HER2-Positive Breast Cancer

Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery

ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D

Phase 2 Window Study of SAR439859 (Amcenestrant) Versus Letrozole in Post-menopausal Patients With ER+, HER2- Pre-operative Post-menopausal Primary Breast Cancer

RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer

A Pharmacodynamics Pre-surgical Study of LEE011 in Early Breast Cancer Patients (MONALEESA-1)

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer

Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene